Clinical Effect Research of Piperacillin/tazobactam in the Treatment of Patients with Stroke Associated Pneumonia

Objective To explore the effectiveness of piperacillin/tazobactam for stroke-associated pneumonia(SAP).Methods 64 patients with stroke associated pneumonia were randomized into treatment group and control group.Treatment group was administered intravenously with piperacillin/tazobactam(2.5g) every 8h for 14 days.Control group was administered intravenously with azithromycin(0.5g/day) for 5 days,and then instead of oral medication.While ceftriaxone injection(3.0g/day) was administered intravenously.The total course of treatment was 14 days,the data of bacteriology and clinical efficacy were collected and analyzed.Results The treatment group and the control group in clinical treatment efficiency were 93.8% and 81.3%,the treatment group and the control group the total bacterial clearance rates were 93.3% and 71.4%,two groups of the comparison of curative effect,the differences were statistically significant(P0.05).The incidence of adverse reactions in treatment group and the control group were respectively 3.1% and 9.4%.Conclusion Piperacillin/tazobactam can be considered as effective drug for stroke-associated pneumonia.